Sales of vitamins within U.S. multi-outlets were up 3.2% to $6.7 billion for the 52 weeks ended June 14 , according to IRI, with no signs of slowing down. Gummy vitamins continue to trend within the multivitamin space, overall sales of which were up 2% to $1.7 billion.
Since the launch of Nexium 24HR in May of 2014, the brand has generated approximately $300 million, “making it one of the largest and most successful Rx-to-OTC switches,” Ian Read, Pfizer chairman and CEO, recently told analysts.
The big story in the digestives space continues to be the switch and launch of Pfizer’s Nexium 24HR. For the 52 weeks ended June 14, sales of Nexium 24HR across total U.S. multi-outlets reached $278.7 million and are still climbing, according to IRI.
Tylenol has retaken the OTC pain relief aisle with a vengeance. The brand is close to reclaiming the top spot among internal analgesic tablets behind Aleve and Advil and is growing at a 10% rate on a dollar base of more than $250 million.
The top four best-selling internal analgesic brands — Advil, Aleve, Tylenol and Bayer — generate more than 40% of the overall $3.3 billion in internal analgesic tablet sales, according to IRI figures. But it’s the smaller niche external analgesic brands that are contributing a lot of incremental sales to the pain relief category.
DSN has partnered with Competitive Promotion Report (CPR) and IRI to create a series of exclusive reports. This article highlights the market performance of major brands in the pain category for both the internal and external analgesic segments.
The National Association of Chain Drug Stores will host a Vision 2026 platform at the Total Store Expo this month in Denver. Here, DSN previews a few of the companies that will be participating in Vision 2026 by offering their perspectives on the changes ahead in retail and health care in the years to come.